AU2017366879C1 - Polymorphs of sepiapterin and salts thereof - Google Patents

Polymorphs of sepiapterin and salts thereof Download PDF

Info

Publication number
AU2017366879C1
AU2017366879C1 AU2017366879A AU2017366879A AU2017366879C1 AU 2017366879 C1 AU2017366879 C1 AU 2017366879C1 AU 2017366879 A AU2017366879 A AU 2017366879A AU 2017366879 A AU2017366879 A AU 2017366879A AU 2017366879 C1 AU2017366879 C1 AU 2017366879C1
Authority
AU
Australia
Prior art keywords
free base
crystalline form
sepiapterin
sepiapterin free
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017366879A
Other languages
English (en)
Other versions
AU2017366879B2 (en
AU2017366879A1 (en
Inventor
Daniel E. Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics MP Inc filed Critical PTC Therapeutics MP Inc
Publication of AU2017366879A1 publication Critical patent/AU2017366879A1/en
Assigned to PTC THERAPEUTICS MP, INC. reassignment PTC THERAPEUTICS MP, INC. Amend patent request/document other than specification (104) Assignors: CENSA PHARMACEUTICALS INC.
Publication of AU2017366879B2 publication Critical patent/AU2017366879B2/en
Priority to AU2022203481A priority Critical patent/AU2022203481B2/en
Application granted granted Critical
Publication of AU2017366879C1 publication Critical patent/AU2017366879C1/en
Priority to AU2024200344A priority patent/AU2024200344B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2017366879A 2016-11-29 2017-11-28 Polymorphs of sepiapterin and salts thereof Active AU2017366879C1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022203481A AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427,686 2016-11-29
US201762546390P 2017-08-16 2017-08-16
US62/546,390 2017-08-16
PCT/US2017/063517 WO2018102315A1 (en) 2016-11-29 2017-11-28 Polymoprhs of sepiapterin and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022203481A Division AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof

Publications (3)

Publication Number Publication Date
AU2017366879A1 AU2017366879A1 (en) 2019-05-30
AU2017366879B2 AU2017366879B2 (en) 2022-02-24
AU2017366879C1 true AU2017366879C1 (en) 2022-08-11

Family

ID=62241930

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017366879A Active AU2017366879C1 (en) 2016-11-29 2017-11-28 Polymorphs of sepiapterin and salts thereof
AU2022203481A Active AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A Active AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022203481A Active AU2022203481B2 (en) 2016-11-29 2022-05-23 Polymorphs of sepiapterin and salts thereof
AU2024200344A Active AU2024200344B2 (en) 2016-11-29 2024-01-18 Polymorphs of sepiapterin and salts thereof

Country Status (14)

Country Link
US (4) US11072614B2 (enExample)
EP (1) EP3548497A4 (enExample)
JP (3) JP7148533B2 (enExample)
KR (3) KR102561697B1 (enExample)
CN (2) CN116903624A (enExample)
AU (3) AU2017366879C1 (enExample)
BR (1) BR122021026889A8 (enExample)
CA (1) CA3043502A1 (enExample)
CO (1) CO2019006018A2 (enExample)
IL (2) IL266955B2 (enExample)
MA (1) MA46973A (enExample)
MX (3) MX386520B (enExample)
NZ (1) NZ753504A (enExample)
WO (1) WO2018102315A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) * 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법
AU2021209935A1 (en) 2020-01-24 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating Parkinson's disease with sepiapterin
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
WO2023055923A1 (en) 2021-09-29 2023-04-06 Ptc Therapeutics, Inc. Pharmaceutical composition of sepiapterin
WO2024249602A2 (en) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ES2177654T3 (es) 1994-08-05 2002-12-16 Suntory Ltd Remedio contra la degeneracion espinocerebelosa.
EP0854934A4 (en) 1995-08-18 2000-09-06 Donald W Landry DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005041975A1 (en) 2003-10-31 2005-05-12 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases
JP2007536210A (ja) 2003-11-17 2007-12-13 メルック・エプロバ・アクチエンゲゼルシヤフト （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形
HUE029533T2 (en) 2003-11-17 2017-03-28 Biomarin Pharm Inc Treatment of phenylketonuria with BH4
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
EP2436379A1 (en) 2004-11-17 2012-04-04 BioMarin Pharmaceutical Inc. Stable tablet formulation
EP1819340A2 (en) * 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
DK3461503T3 (da) * 2007-04-11 2022-02-14 Biomarin Pharm Inc Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
NZ588379A (en) * 2008-03-10 2012-07-27 Takeda Pharmaceutical Crystal of benzimidazole compound
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) * 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
EP2680848A4 (en) 2011-03-01 2014-11-05 Rubicon Res Private Ltd STABLE TETRAHYDROBIOPTERINE COMPOSITIONS
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
AU2017286544B2 (en) 2016-06-13 2022-10-20 Meharry Medical College Modulation of the nitric oxide synthase pathway for oral health
JP2019527242A (ja) 2016-07-29 2019-09-26 ディファーマ エッセ．ア． サプロプテリンジヒドロクロリドを含む医薬組成物キット
IL266955B2 (en) 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
WO2018102314A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
WO2019046849A1 (en) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF
CA3102070A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534A4 (en) 2018-05-30 2022-03-16 PTC Therapeutics MP, Inc. COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE
SMT202400430T1 (it) 2018-05-30 2024-11-15 Ptc Therapeutics Mp Inc Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina
ES2994060T3 (en) 2019-08-05 2025-01-16 Ptc Therapeutics Mp Inc Use of sepiapterin and metabolites thereof to treat radiation exposure
KR20220070477A (ko) 2019-09-25 2022-05-31 피티씨 테라퓨틱스 엠피, 인크. 고페닐알라닌혈증 치료 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181254B2 (en) * 2012-05-07 2015-11-10 Shiratori Pharmaceutical Co., Ltd. Method for producing sepiapterin and tetrahydrolactoylpterin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pfleiderer, W., "Pteridine, LXVIII. Überführung von Biopterin in Sepiapterin und absolute Konfiguration des Sepiapterins." Chemische Berichte, 1979, 112(7), pp: 2750-2755 *
Schircks, B., et al. "Herstellung von (6R,S)5,6,7,8Tetrahydrolbiopterin, 7,8Dihydrolbiopterin, lSepiapterin, Deoxysepiapterin, (6R,S)5,6Dihydrodeoxysepiapterin und 2′Deoxybiopterin." Helv. Chim. Acta, 1978, 61(7), 2731-38 *

Also Published As

Publication number Publication date
CN110248948B (zh) 2023-07-28
AU2017366879B2 (en) 2022-02-24
CN110248948A (zh) 2019-09-17
EP3548497A1 (en) 2019-10-09
MA46973A (fr) 2019-10-09
BR112019010222A2 (pt) 2019-08-27
BR112019010222A8 (pt) 2022-11-22
WO2018102315A1 (en) 2018-06-07
MX2021011676A (es) 2021-10-22
BR122021026889A2 (enExample) 2019-08-27
KR20190086686A (ko) 2019-07-23
MX2021011683A (es) 2021-10-22
WO2018102315A8 (en) 2018-09-07
CN116903624A (zh) 2023-10-20
CO2019006018A2 (es) 2019-06-19
US20250230164A1 (en) 2025-07-17
US11773097B2 (en) 2023-10-03
AU2024200344A1 (en) 2024-02-08
IL266955B2 (en) 2023-09-01
US20190308975A1 (en) 2019-10-10
IL301470A (en) 2023-05-01
AU2024200344B2 (en) 2025-11-06
JP7148533B2 (ja) 2022-10-05
EP3548497A4 (en) 2020-09-02
US20210300930A1 (en) 2021-09-30
JP2023002532A (ja) 2023-01-10
US11072614B2 (en) 2021-07-27
IL266955A (en) 2019-07-31
KR20250051124A (ko) 2025-04-16
KR20230117467A (ko) 2023-08-08
AU2022203481B2 (en) 2023-10-19
JP2024123011A (ja) 2024-09-10
AU2017366879A1 (en) 2019-05-30
JP2019535836A (ja) 2019-12-12
KR102789662B1 (ko) 2025-04-03
AU2022203481A1 (en) 2022-06-16
MX386520B (es) 2025-03-19
KR102561697B1 (ko) 2023-07-28
CA3043502A1 (en) 2018-06-07
US12269829B2 (en) 2025-04-08
IL266955B1 (en) 2023-05-01
MX2019006206A (es) 2019-08-14
US20240043426A1 (en) 2024-02-08
NZ753504A (en) 2025-10-31
BR122021026889A8 (pt) 2022-11-22

Similar Documents

Publication Publication Date Title
AU2022203481B2 (en) Polymorphs of sepiapterin and salts thereof
US12325706B2 (en) Polymorphic form of sepiapterin
JP7778477B2 (ja) セピアプテリンの薬学的に許容される塩
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas
RU2851633C1 (ru) Соединения хиназолина, содержащие спиро-кольцо
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PTC THERAPEUTICS MP, INC.

Free format text: FORMER NAME(S): CENSA PHARMACEUTICALS INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 MAY 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 MAY 2022

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: SEPHIENCE SEPIAPTERIN

Filing date: 20250717

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: SEPHIENCE SEPIAPTERIN

Filing date: 20250717